Skip to content
DataLookout
Menu

NCT05795244

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 167 words Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Trial sites expanded: 1 → 6 locations
    • Primary completion date changed from estimate of Dec 2029 to Feb 24, 2026
    • Study completion date: Dec 2029 to Dec 31, 2029
    • Secondary endpoints: 3 to 4
    • Publications: details revised at 1 of 1 entry
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2023 to Oct 31, 2023
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

pathologic complete response
Timeframe: At 6 months

Secondary (4)

Objective response rate (ORR)
Progression free survival (PFS)
Overall survival (OS)
Incidence of Treatment-Emergent Adverse Events (TEAEs)

Arms and interventions

ExperimentalExperimental

Drugs: Nivolumab

Sites

6 sites in 1 country